PLUS1
48.99
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| FibroGen Inc | FGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 48.99 | 08:48:16 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 48.99 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 47.04 | 48.00 | 0.96 | 1 | - |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 5 | 17 | 875,182 | 22.65 - 53.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:12:15 | 4 | $ 48.00 | USD |
FibroGen Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.46B | 91.01M | 79.57M | $ 256.58M | $ - | -0.96 | -18.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
FibroGen News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/27/2021 | 06:00 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/07/2021 | 10:04 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 12/30/2020 | 18:08 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 12/22/2020 | 07:00 | GlobeNewswire Inc. | FibroGen Advances Phase 3 Clinical Development of.. |
| 12/21/2020 | 12:25 | Dow Jones News | FibroGen Down; FDA Extends Review Period for Roxadustat |
| 12/18/2020 | 17:11 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/18/2020 | 16:59 | GlobeNewswire Inc. | FibroGen Provides Regulatory Update on Roxadustat |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FGEN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 44.40 | 50.6416 | 44.05 | 47.63 | 688,180 | 4.59 | 10.34% |
| 1 Month | 37.92 | 50.6416 | 36.86 | 42.03 | 687,196 | 11.07 | 29.19% |
| 3 Months | 39.89 | 50.6416 | 36.86 | 41.57 | 739,928 | 9.10 | 22.81% |
| 6 Months | 42.60 | 53.97 | 36.86 | 42.34 | 705,666 | 6.39 | 15.0% |
| 1 Year | 40.74 | 53.97 | 22.65 | 39.94 | 695,111 | 8.25 | 20.25% |
| 3 Years | 58.40 | 68.55 | 22.65 | 44.61 | 636,865 | -9.41 | -16.11% |
| 5 Years | 20.57 | 68.55 | 14.38 | 40.15 | 585,490 | 28.42 | 138.16% |
FibroGen Description
| FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. |
